𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy

✍ Scribed by Javier Vaquero; Robert J. Fontana; Anne M. Larson; Nathan M.T. Bass; Timothy J. Davern; A. Obaid Shakil; Steven Han; M. Edwyn Harrison; Todd R. Stravitz; Santiago Muñoz; Robert Brown; William M. Lee; Andres T. Blei


Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
256 KB
Volume
11
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

✦ Synopsis


Monitoring of intracranial pressure (ICP) in acute liver failure (ALF) is controversial as a result of the reported complication risk (approximately 20%) and limited therapeutic options for intracranial hypertension. Using prospectively collected information from 332 patients with ALF and severe encephalopathy, we evaluated a recent experience with ICP monitoring in the 24 centers constituting the U.S. ALF Study Group. Special attention was given to the rate of complications, changes in management, and outcome after liver transplantation (LT). ICP monitoring was used in 92 patients (28% of the cohort), but the frequency of monitoring differed between centers (P < 0.001). ICP monitoring was strongly associated with the indication of LT (P < 0.001). A survey performed in a subset of 58 patients with ICP monitoring revealed intracranial hemorrhage in 10.3% of the cohort, half of the complications being incidental radiological findings. However, intracranial bleeding could have contributed to the demise of 2 patients. In subjects listed for LT, ICP monitoring was associated with a higher proportion of subjects receiving vasopressors and ICP-related medications. The 30-day survival post-LT was similar in both monitored and nonmonitored groups (85% vs. 85%). In conclusion, the risk of intracranial hemorrhage following ICP monitoring may have decreased in the last decade, but major complications are still present. In the absence of ICP monitoring, however, patients listed for LT appear to be treated less aggressively for intracranial hypertension. In view of the high 30-day survival rate after LT, future studies of the impact of intracranial hypertension should also focus on long-term neurological recovery from ALF.


📜 SIMILAR VOLUMES


Intracranial pressure monitoring in pati
✍ Jacques Bernuau; François Durand 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

Monitoring of intracranial pressure (ICP) in acute liver failure (ALF) is controversial as a result of the reported complication risk (approximately 20%) and limited therapeutic options for intracranial hypertension. Using prospectively collected information from 332 patients with ALF and severe enc

Intracranial pressure monitoring in acut
✍ Julia A. Wendon; Fin Stolze Larsen 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB 👁 1 views

tures (etiology, hemodynamic condition, arterial ammonia, spontaneous activity of coagulation factors, serum creatinine, natremia) allowing to exclude from monitoring those patients with the highest probability of spontaneous survival. However, the best answer to the abovementioned challenge is, whe

Noninvasive monitoring of cerebral perfu
✍ Shushma Aggarwal; David M. Brooks; Yoogoo Kang; Peter K. Linden; John F. Patzer 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 366 KB

Elevated intracranial pressure (ICP) leads to loss of cerebral perfusion, cerebral herniation, and irreversible brain damage in patients with acute liver failure (ALF). Conventional techniques for monitoring ICP can be complicated by hemorrhage and infection. Transcranial doppler ultrasonography (TC

The effect of hypertonic sodium chloride
✍ Nicholas Murphy; Georg Auzinger; William Bernel; Julia Wendon 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 1 views

Acute liver failure (ALF) is a rare condition characterized by the development of encephalopathy in the absence of chronic liver disease. Cerebral edema occurs in up to 80% of patients with Grade IV encephalopathy. In the current prospective randomized controlled clinical trial, we examined the effe

Worsening of cerebral hyperemia by the a
✍ Debbie L. Shawcross; Nathan A. Davies; Rajeshwar P. Mookerjee; Peter C. Hayes; R 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 1 views

There is increasing evidence that terlipressin is useful in patients with cirrhosis and hepatorenal syndrome, but there are no data of its use in patients with acute liver failure (ALF) in whom hepatorenal syndrome is common. Although terlipressin produces systemic vasoconstriction, it produces cere